NICE’s menopause guideline NG23 was last reviewed on 15 April 2026. In the UK, the test is no longer whether HRT exists, but whether symptoms are recognised early, a GP appointment is available, and the prescription arrives without confusion or delay. Menopause care is broader than HRT alone and still uneven at the point where women first ask for help.
NICE has widened the frame
Its remit is explicit: identifying and managing menopause, including in people with premature ovarian insufficiency, while improving the consistency of support and information. Perimenopausal symptoms can be disruptive before periods stop, so the clinical conversation starts earlier than many women expect.
The April 2026 update amended recommendation 1.8.4 and added 1.8.5 on unscheduled vaginal bleeding while taking systemic HRT, bringing the menopause guideline into line with NICE’s suspected-cancer guidance. The November 2024 review also added or refreshed recommendations on cognitive behavioural therapy for menopausal symptoms and on managing genitourinary symptoms. The changes cover unscheduled bleeding, cognitive behavioural therapy and genitourinary symptoms as well as HRT.
The HRT debate is now about fit, not slogans
The British Menopause Society lists the updated NG23 as published in November 2024. Around the same time, specialist guidance on unscheduled bleeding on HRT was developed with the British Society of Gynaecological Endoscopy, the British Gynaecological Cancer Society, the Faculty of Sexual and Reproductive Healthcare, Getting It Right First Time, the Royal College of General Practitioners and the Royal College of Obstetricians and Gynaecologists.
The clinical argument is no longer about whether every woman should be funnelled into the same treatment plan. Mary Ann Lumsden and Sarah Hardman argued in BMJ that NICE menopause guidance still lacks nuance and that treatment requires a personalised approach. Dr Nighat Arif called it “a step in the right direction” while saying more guidance is needed for people affected by cancer, endometriosis, PCOS, ADHD and neurodegenerative disease. The more complex the history, the less consistent the pathway can become.
See your GP promptly if you have unscheduled vaginal bleeding while taking systemic HRT. NICE has tied that issue directly to its suspected-cancer guidance, which makes it a review item, not a nuisance symptom to park until the next routine appointment.
Access is where women still get stuck
The research on lived access does not show a tidy system. A 2025 qualitative study in the British Journal of General Practice examined women’s experiences of accessing equitable menopause care in the contemporary NHS. The study record described menopause as particularly disruptive to modern women and found that women are often dissatisfied with the options available.
A separate University of Birmingham study on GP clinician experiences in diverse communities, with an early online date of 6 June 2025, found that clinicians themselves see menopause care as hard to deliver fairly across communities. Women who reach a knowledgeable GP or specialist menopause service are more likely to get a coherent plan. Women who do not are more likely to be bounced between appointments, repeat histories and inconsistent advice.
Getting to the right decision now depends on whether the first clinician recognises perimenopause early, knows when bleeding changes the risk calculation, and can handle symptom patterns that sit outside a simple textbook case.
What the appointment needs to cover
A good menopause consultation now has to do several jobs at once. It should identify whether symptoms fit perimenopause, check whether bleeding is expected or unscheduled, and decide whether HRT is the right option or whether another route is needed. Because NG23 now includes cognitive behavioural therapy and genitourinary symptom management, the conversation should not stop at hormones.
Useful questions to put to the clinician are straightforward:
- Do my symptoms fit perimenopause, and what else could explain them?
- If I am on systemic HRT and have bleeding, what happens next?
- Do my genitourinary symptoms need separate treatment?
- Is cognitive behavioural therapy part of my plan, or should it be considered alongside treatment?
- If I have a history of cancer, endometriosis, PCOS, ADHD or a neurodegenerative condition, what guidance are you using to decide whether systemic HRT is appropriate?
- If this cannot be handled in one appointment, what is the route to a specialist menopause service?
The access problem is often administrative as much as clinical. Women are not just looking for a diagnosis. They are trying to get through reception, secure enough time in the appointment, and leave with a prescription or referral that does not trigger another loop of uncertainty.
Workplace policy is now part of the same story
Menopause has also become an employment issue. The House of Commons Women and Equalities Committee published its report on menopause and the workplace on 28 July 2022, and GOV.UK’s menopause-in-the-workplace literature review and progress report treat it as an economic and employment question, not only a medical one.
Employers, occupational-health teams, private clinics and digital triage services are all now part of the same market.